Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 16/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.35 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739291 | 1.00 | TGFBR1 (0.45) | TGFBR1NR1H4TGFBR2EPHB3CLK1 | |
| SCHEMBL14738786 | 0.82 | TGFBR1 (0.62) | TGFBR1 | |
| SCHEMBL14738785 | 0.82 | TGFBR1 (0.62) | TGFBR1 | |
| SCHEMBL14738353 | 0.80 | TGFBR1 (0.48) | TGFBR1NR1H4TGFBR2CLK1 | |
| SCHEMBL14738352 | 0.80 | TGFBR1 (0.48) | TGFBR1NR1H4TGFBR2CLK1 | |
| SCHEMBL14738703 | 0.78 | TGFBR1 (0.50) | TGFBR1NR1H4TGFBR2 | |
| SCHEMBL14738704 | 0.78 | TGFBR1 (0.50) | TGFBR1NR1H4TGFBR2 | |
| SCHEMBL9941943 | 0.76 | TGFBR1 (0.44) | TGFBR1TGFBR2EPHB3CLK1 | |
| SCHEMBL2049652 | 0.74 | TGFBR1 (0.43) | TGFBR1TGFBR2EPHB3CLK1 | |
| SCHEMBL22955835 | 0.73 | TGFBR1 (0.81) | TGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751104-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-09-25 | — | — | EP | disclosed |
| EP-2751102-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| US-9199981-B2 | Compounds and compositions as C-kit kinase inhibitors | NOVARTIS AG (CH) | 2015-12-01 | — | — | US | disclosed |
| US-9023839-B2 | Compounds and compositions as c-kit kinase inhibitors | IRM LLC (BM) | 2015-05-05 | — | — | US | disclosed |
| US-20150051206-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2015-02-19 | — | — | US | disclosed |
| US-20150011508-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2015-01-08 | — | — | US | disclosed |
| US-20140228347-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-08-14 | — | — | US | disclosed |
| EP-2751105-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-07-09 | — | — | EP | disclosed |
| EP-2751104-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-07-09 | — | — | EP | disclosed |
| EP-2751102-A1 | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-07-09 | — | — | EP | disclosed |
| EP-2751103-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-07-09 | — | — | EP | disclosed |
| US-8754071-B2 | Compounds and compositions as c-kit kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-06-17 | — | — | US | disclosed |
| US-20140031333-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-01-30 | — | — | US | disclosed |
| US-8569283-B2 | Compounds and compositions as c-Kit kinase inhibitors | IRM LLC (BM) | 2013-10-29 | — | — | US | disclosed |
| WO-2013033167-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033116-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033070-A1 | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | disclosed |
| WO-2013033203-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059846-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051206-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | TGFBR1 2326/4885NR1H4 4610/4885TGFBR2 2087/4885 |
| US-20140031333-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | TGFBR1 2326/4885NR1H4 4610/4885TGFBR2 2087/4885 |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | TGFBR1 2326/4885NR1H4 4610/4885TGFBR2 2087/4885 |
| US-20150011508-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | TGFBR1 1802/4885NR1H4 4439/4885TGFBR2 1468/4885 |
| US-20140228347-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | TGFBR1 2326/4885NR1H4 4610/4885TGFBR2 2087/4885 |
| US-20130059846-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | TGFBR1 2326/4885NR1H4 4610/4885TGFBR2 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.